VIRX

NASDAQ

Viracta Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2005

News25/Ratings2

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.

Latest news

25 items

442dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
442dPR
Viracta Therapeutics Announces Wind Down of Operations
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of
447dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
454dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
461dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
483dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update, Other Events, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
483dPR
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety find
510dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
512dINSIDER
Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 839,741 units (SEC Form 4)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
512dINSIDER
Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 126,478 units (SEC Form 4)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
517dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
525d13D/G
Amendment: SEC Form SC 13G/A filed by Viracta Therapeutics Inc.
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
526dSEC
SEC Form 10-Q filed by Viracta Therapeutics Inc.
10-Q - Viracta Therapeutics, Inc. (0001061027) (Filer)
526dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
526dPR
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 - - Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors - SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial
533dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
533dPR
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the company has implemented a reprioritization of resources intended to enhance the company's focus on its Nana-val development program in patients with relapsed or refractory (R/R) EBV-positive peripheral T-cell lymphoma (PTCL). To further align resources with current pipeline priorities, Viracta is announcing today that it has implemented a further reduction in force that impacts approximately 42% of the company's employees. Viracta ex
588dINSIDER
Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 814,522 units (SEC Form 4)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
588dINSIDER
Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 117,444 units (SEC Form 4)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
597dPR
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place in New York City on Wednesday, September 11, 2024, at 8:30 a.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Presentations" and archived for 90 days. About Viracta Therapeutics, Inc.Viracta is a clinical-stage precision o
615dANALYST
Viracta Therapeutics downgraded by Leerink Partners with a new price target
Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously
617dSEC
SEC Form 10-Q filed by Viracta Therapeutics Inc.
10-Q - Viracta Therapeutics, Inc. (0001061027) (Filer)
617dSEC
Viracta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
617dPR
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - New positive data and productive feedback from the FDA support updated Nana-val clinical development plan in EBV-positive PTCL patients; randomized controlled trial planned to begin in the second half of 2025 to support potential registration - - Appointed Michael Faerm as Chief Financial Officer - SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology
617dPR
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8: